weak expect
materi late pressur suspend full-year guidanc
came expect capit rais address liquid
extend runway decis around commerci strategi
pt
pre-announce preliminari result close expect
exhibit signific late quarter pressur persist rest
cut number materi last week identifi phase
recoveri stori like see acut pressur somewhat delay
recoveri versu emerg procedur note new
normal medic devic last week
quarter revenu consensu
direct consist preliminari opex larg line
mse adjust cancel procedur result would
larg line street high prior estim
look beyond full year guidanc suspend expect
lower estim last week
street revis estim
respect reflect signific
procedur impact month april may
june repres quarterli hit y/i declin rel
hit y/i declin prior estim also lower
estim reflect y/i drop vs prior remain construct
recoveri estim recoveri quarter prior
rel previou estim worth note typic see
convers trial perman implant compani
mention perform trial patient await
perman implant leav us comfort recoveri path
throughout balanc support backlog
strategi remain comfort liquid posit prior
offer compani cash cash equival short-
term invest forma equiti net proce
medic technolog unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
convert offer price morn togeth
retir substanti exist convert due compani
cash liquid on-going omnia launch well
catalyst pdn nsrbp sens like stay front
foot commerci hold salesforc ration re-evaluate
strategi time light diseas progress given recent offer
adequ liquid support decis
price target support dcf reect multipl
base case sale line high growth smid cap med-tech comp group includ
npv upsid pdn penetr like impact procedur acut
durabl peer base case
believ new platform launch
late catalyz acceler
share gain
clinic data expand key
data pain diabet neuropathi non-
surgic back come
competit risk clinic
product perspect well understood
view descript risk reward theme
impact mute
expect ofc procedur
materi share gain expans
market growth near term acceler
innov new indic
progress faster timelin expect
combin better expect
share gain particularli around pdn
nsrbp drive sale
acceler high teen lead
substanti re-rat multipl
base case sale support
impact meaning
durabl peer
headwind omnia launch late
launch lead materi acceler
share gain grow
primarili crystal pdn opportun
drive market growth enthusiasm
come pdn data readout
recoveri prolong well
growth slow competit headwind
less differenti omnia launch
fail catalyz sale less
differenti combin upstart
competit execut issu lead
growth mid singl digit lead
pt increment ww share
pt increment us share
pt increment us market growth
assum pro rata share impli
china india
view explan region hierarchi
research highest favor quintil
procedur impact expect
pdn penetr progress faster
expect reach revenu year
nsrbp penetr ramp faster
omnia launch fail catalyz sale
upstart competitor could acquir and/or
obtain fund launch take materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
financi exhibit
good sold
accumul comprehens loss
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc
purchas invest
proce matur invest
chang restrict cash
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas proce issuanc common stock stock option exercis
begin period
end period
sale
sale
sale
sale
